A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report

Conclusions
Veliparib and TMZ at the RP2D were well tolerated in children with recurrent brain tumors. A phase I/II trial to evaluate the tolerability and efficacy of veliparib, TMZ, and radiation in children with newly diagnosed brainstem gliomas is in progress.

Source: Neuro-Oncology - November 14, 2014 Category: Cancer & Oncology Authors: Su, J. M., Thompson, P., Adesina, A., Li, X.-N., Kilburn, L., Onar-Thomas, A., Kocak, M., Chyla, B., McKeegan, E., Warren, K. E., Goldman, S., Pollack, I. F., Fouladi, M., Chen, A., Giranda, V., Boyett, J., Kun, L., Blaney, S. M. Tags: Pediatric Neuro-Oncology Source Type: research